​

Arrowhead Pharmaceuticals (ARWR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ARWR Stock Forecast

Arrowhead Pharmaceuticals (ARWR) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $26.99, with a high of $29.97 and a low of $24.00. This represents a 140.12% increase from the last price of $11.24.

$10 $15 $20 $25 $30 $35 High: $29.97 Avg: $26.99 Low: $24 Last Closed Price: $11.24

ARWR Stock Rating

Arrowhead Pharmaceuticals stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (78.95%), 4 Hold (21.05%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 4 15 Strong Sell Sell Hold Buy Strong Buy

ARWR Price Target Upside V Benchmarks

TypeNameUpside
StockArrowhead Pharmaceuticals140.12%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--6
Avg Price Target--$27.82
Last Closing Price$11.24$11.24$11.24
Upside/Downside--147.51%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25375--15
Mar, 25375--15
Feb, 25375--15
Jan, 25375--15
Dec, 24375--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 29, 2024William PickeringBernstein$24.00$25.81-7.01%113.52%
Nov 27, 2024Keay NakaeLoop Capital Markets$29.97$12.90132.33%166.64%
Sep 03, 2024David LebowitzCitigroup$27.00$22.9117.85%140.21%
Jul 05, 2024Patrick TrucchioH.C. Wainwright$29.97$12.77134.69%166.64%
Jun 05, 2024Andrea TanGoldman Sachs$31.00$25.2922.58%175.80%
May 30, 2024Luca IssiRBC Capital$24.98$11.43118.55%122.24%
Feb 07, 2023RBC Capital$38.46$16.45133.80%242.17%
Feb 07, 2023Piper Sandler$52.00$33.5155.18%362.63%
Dec 06, 2022H.C. Wainwright$44.96$15.75185.46%300.00%
Nov 29, 2022Jefferies$37.47$14.99149.97%233.36%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 29, 2024BernsteinMarket PerformMarket Performhold
Nov 27, 2024Piper SandlerOverweightOverweighthold
Nov 27, 2024Chardan CapitalBuyBuyhold
Nov 18, 2024CitigroupNeutralNeutralhold
Oct 14, 2024H.C. WainwrightBuyBuyhold
Sep 04, 2024H.C. WainwrightBuyBuyhold
Sep 03, 2024CitigroupNeutralNeutralhold
Aug 21, 2024Cowen & Co.BuyBuyhold
Aug 15, 2024Piper SandlerOverweightOverweighthold
Jul 05, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Sep 20 Sep 21 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 20Sep 21Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-0.84$-1.36$-1.67$-1.91$-5.00-----
Avg Forecast$-0.25$-0.69$-1.61$-1.50$-4.70$-2.52$-3.41$-2.77$-2.25$0.18
High Forecast$0.05$0.13$-1.28$-1.18$-3.31$0.74$0.11$-1.55$0.20$0.54
Low Forecast$-0.59$-1.61$-1.93$-1.68$-5.58$-3.68$-5.31$-3.38$-6.94$-0.02
Surprise %236.00%97.10%3.73%27.33%6.38%-----

Revenue Forecast

$0 $500M $1B $2B $2B $3B Sep 20 Sep 21 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 20Sep 21Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$87.99M$138.29M$243.23M$240.74M$3.55M-----
Avg Forecast$132.14M$134.59M$1.18B$263.61M$62.14M$313.93M$231.30M$353.55M$479.98M$935.02M
High Forecast$266.83M$271.79M$1.42B$313.09M$163.61M$893.72M$667.69M$361.18M$1.25B$2.44B
Low Forecast$12.05M$12.28M$943.36M$234.10M$2.29M$16.28M$58.70M$345.92M$77.43M$150.83M
Surprise %-33.41%2.75%-79.37%-8.68%-94.29%-----

Net Income Forecast

$-850M $-660M $-470M $-280M $-90M $100M Sep 20 Sep 21 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 20Sep 21Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-84.55M$-140.85M$-176.49M$-205.28M$-599.49M-----
Avg Forecast$-352.71M$-349.03M$-98.54M$-296.81M$-599.49M$-361.23M$-510.08M$-397.66M$-269.21M$20.96M
High Forecast$-282.17M$-279.22M$34.96M$-13.39M$-396.88M$88.77M$12.85M$-185.57M$24.31M$64.76M
Low Forecast$-423.26M$-418.83M$-232.05M$-580.24M$-668.42M$-440.31M$-635.88M$-404.78M$-831.65M$-1.89M
Surprise %-76.03%-59.65%79.10%-30.84%------

ARWR Forecast FAQ

Is Arrowhead Pharmaceuticals stock a buy?

Arrowhead Pharmaceuticals stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Arrowhead Pharmaceuticals is a favorable investment for most analysts.

What is Arrowhead Pharmaceuticals's price target?

Arrowhead Pharmaceuticals's price target, set by 19 Wall Street analysts, averages $26.99 over the next 12 months. The price target range spans from $24 at the low end to $29.97 at the high end, suggesting a potential 140.12% change from the previous closing price of $11.24.

How does Arrowhead Pharmaceuticals stock forecast compare to its benchmarks?

Arrowhead Pharmaceuticals's stock forecast shows a 140.12% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Arrowhead Pharmaceuticals over the past three months?

  • April 2025: 20.00% Strong Buy, 46.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 20.00% Strong Buy, 46.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 20.00% Strong Buy, 46.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Arrowhead Pharmaceuticals’s EPS forecast?

Arrowhead Pharmaceuticals's average annual EPS forecast for its fiscal year ending in September 2025 is $-2.52, marking a -49.60% decrease from the reported $-5 in 2024. Estimates for the following years are $-3.41 in 2026, $-2.77 in 2027, $-2.25 in 2028, and $0.18 in 2029.

What is Arrowhead Pharmaceuticals’s revenue forecast?

Arrowhead Pharmaceuticals's average annual revenue forecast for its fiscal year ending in September 2025 is $313.93M, reflecting a 8740.62% increase from the reported $3.55M in 2024. The forecast for 2026 is $231.3M, followed by $353.55M for 2027, $479.98M for 2028, and $935.02M for 2029.

What is Arrowhead Pharmaceuticals’s net income forecast?

Arrowhead Pharmaceuticals's net income forecast for the fiscal year ending in September 2025 stands at $-361M, representing a -39.74% decrease from the reported $-599M in 2024. Projections indicate $-510M in 2026, $-398M in 2027, $-269M in 2028, and $20.96M in 2029.